HLN Stock Analysis: Buy, Sell, or Hold?
HLN - Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$8.80
0.08 (0.92%)
▲
5d:
-4.97%
30d:
-11.2%
90d:
-9.47%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When HLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: HLN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: HLN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.98
Based on 6.7% avg growth
INTRINSIC VALUE TODAY
$8.68
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HLN is currently trading at $8.80, which is considered oversold relative to its 30-day fair value range of $9.03 to $9.90. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.2) compared to its historical average (16.4). Remarkably, the market is currently pricing in an annual earnings decline of 4.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is currently testing key support at $8.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HLN scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.93 (+35.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is currently testing key support at $8.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HLN scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.93 (+35.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.03 -
$9.90
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.6% below Wall St target ($11.93)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.03 -
$9.90
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.67
Resistance Level
$9.39
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.24
Wall Street Target
$11.93
(+35.6%)
Revenue Growth (YoY)
2.2%
Earnings Growth (YoY)
-4.5%
Profit Margin
14.5%
Valuation Discount vs History
-4.6% cheaper
PE vs Historical
14.2 vs 16.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.6%
(market-implied from PE analysis)
1-Year Target
$8.40
(-5%)
2-Year Target
$8.01
(-9%)
3-Year Target
$7.64
(-13%)
3-Yr Target (if PE normalizes)
(PE: 14→16)
$8.80
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 9.3%)
$16.46
(+87%)
Base:
(SPY PE: 14.2, Growth: 9.3%)
$11.48
(+31%)
Bear:
(PE: 12.1, Growth: 9.3%)
$9.76
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 18.17 | Current EPS (TTM): $0.48
Bull Case
$12.35
(+40%)
Analyst growth 28.8%, PE expands to 20.0
Base Case
$11.23
(+28%)
Market implied 28.8%, PE stable at 18.2
Bear Case
$5.93
(-33%)
Severe decline -20.0%, PE contracts to 15.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.2 to 16.4
Stabilization Target:
$10.14
(+15.2%)
PE Expansion Potential:
+15.2%
Share & Embed Analysis
Last updated: October 03, 2026 4:14 PM ET
Data refreshes hourly during market hours. Next update: 5:14 PM
Data refreshes hourly during market hours. Next update: 5:14 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
